PP
MCRB icon

Paloma Partners’s Seres Therapeutics MCRB Stock Holding History

Paloma Partners’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,552
Closed -$80.4K – 1469
2024
Q2 		$80.4K Buy
+5,552
New +$92.6K ﹤0.01% 1098
2021
Q2 		– Sell
-991
Closed -$408K – 2066
2021
Q1 		$408K Buy
+991
New +$456K 0.01% 1276
2018
Q4 		– Sell
-970
Closed -$147K – 1587
2018
Q3 		$147K Buy
+970
New +$157K ﹤0.01% 1426

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Paloma Partners's MCRB Position: Q3 2024 in Review

Paloma Partners sold out of Seres Therapeutics (MCRB) in Q3 2024, closing a stake of 5,552 shares — an estimated $80.4K sold.

Paloma Partners first reported a position in MCRB in Q3 2018 and held it in 3 quarters. The position peaked at $408K in Q1 2021. 77 funds tracked by Wall St. Rank hold MCRB as of Q3 2024.

  • Paloma Partners reported no remaining Seres Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Paloma Partners sold 5,552 Seres Therapeutics shares in Q3 2024, an estimated $80.4K.
  • Paloma Partners first reported a position in Seres Therapeutics in Q3 2018 and held it in 3 quarters.
  • Paloma Partners's Seres Therapeutics position peaked at $408K in Q1 2021.
  • 77 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2024.

Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.